Interferon alfa-2b is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase II for Genital Warts (Condylomata Acuminata). According to GlobalData, Phase II drugs for Genital Warts (Condylomata Acuminata) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Interferon alfa-2b’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Interferon alfa-2b overview
Interferon alfa-2b is under development for the treatment of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), genital warts and respiratory tract infections. It is administered by subcutaneous, sublingual, intramuscular and nasal route. It acts by targeting interferon alpha/beta receptor 1 (IFNAR1) and interferon alpha/beta receptor 2 (IFNAR2).
Center for Genetic Engineering and Biotechnology overview
Center for Genetic Engineering and Biotechnology (CIGB) is a biotechnology company that investigates, develops, produces and markets novel biotechnological applications, therapeutic and diagnostic biopharmaceutical products, for the biomedical, agricultural and industrial sectors. CIGB is headquartered in Cuba.
For a complete picture of Interferon alfa-2b’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
